对不起，此内容只适用于English。 For the sake of viewer convenience, the content is shown below in the alternative language. You may click the link to switch the active language.

Even as national attention on IVF continues to grow, the Department of Health and Human Services has recently eliminated the staff responsible for tracking and analyzing fertility treatments in the United States. This comes even after President Trump signed an executive order requesting a list of ideas to protect access to fertility care and lower the cost of IVF. 

For years, the CDC’s Assisted Reproductive Technology Surveillance has been critical in monitoring fertility treatments. This team has been responsible for collecting and reporting data on IVF cycles, success rates, and clinic performance, a resource relied on heavily by patients, providers, and policymakers alike. However, according to current and former officials, the CDC’s IVF team has been “gutted,” with staff reassigned or let go, and a general lack of transparency about the future of the program.

These staffing cuts are raising red flags among reproductive health advocates and medical professionals. Without strong federal oversight, there’s concern that the quality, consistency, and safety of fertility care could suffer. The data collected by the CDC not only informs patient decision-making but also helps shape policy and ensure accountability among clinics. Without it, patients may face challenges finding reliable information about treatment success rates, and lawmakers may be left without the data they need to improve access and care.

This development comes at a time when IVF is more visible and politically discussed than ever before. Following the Alabama Supreme Court ruling that recognized embryos as children last year, leading to a temporary suspension of IVF services in the state, fertility care has become a national flashpoint. President Trump responded by voicing strong support for IVF and signing an executive order intended to reduce treatment costs and improve transparency. Yet, the rollback of support within the CDC appears to contradict this public stance.

Federal investment in reproductive health has declined in recent years, raising concerns among experts about the long-term impact on access to and quality of fertility care. Experts warn that this trend could have long-term consequences for families pursuing assisted reproductive technology. Accurate, up-to-date data is essential for improving outcomes, expanding access, and identifying disparities in care, especially for underserved populations.

As the national conversation around IVF and surrogacy continues, we remain committed to helping families navigate this complex and ever-changing landscape. Whether you’re just beginning to explore your options or are in the middle of the process, our team is here to provide guidance, protection, and peace of mind every step of the way. Contact us today to learn more!